Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (5): 812-817. doi: 10.19723/j.issn.1671-167X.2023.05.006

Previous Articles     Next Articles

Diagnostic efficacy of prostate cancer using targeted biopsy with 6-core systematic biopsy for patients with PI-RADS 5

Yi LIU1,Chang-wei YUAN1,Jing-yun WU2,Qi SHEN1,Jiang-xi XIAO2,*(),Zheng ZHAO1,*(),Xiao-ying WANG2,Xue-song LI1,Zhi-song HE1,Li-qun ZHOU1   

  1. 1. Department of Urology, Peking University First Hospital; Institute of Urology, Peking University; National Urological Cancer Center, Beijing 100034, China
    2. Department of Radiology, Peking University First Hospital, Beijing 100034, China
  • Received:2023-03-13 Online:2023-10-18 Published:2023-10-09
  • Contact: Jiang-xi XIAO,Zheng ZHAO E-mail:cjr.xiaojiangxi@vip.163.com;zzpkufh@163.com
  • Supported by:
    the Scientific Research Seed Fund of Peking University First Hospital(2020SF24)

RICH HTML

 8   

PDF (PC)

139

Abstract:

Objective: To investigate the diagnostic efficacy of targeted biopsy (TBx), systematic biopsy (SBx), TBx+6-core SBx in prostate cancer (PCa) / clinically significant prostate cancer (cs-PCa) for patients with prostate imaging reporting and data system (PI-RADS) score of 5, and thereby to explore an optimal sampling scheme. Methods: The data of 585 patients who underwent multiparametric magnetic resonance imaging (mpMRI) with at least one lesion of PI-RADS score 5 at Peking University First Hospital from January 2019 to June 2022 were retrospectively analyzed. All patients underwent mpMRI / transrectal ultrasound (TRUS) cognitive guided biopsy (TBx+SBx). With the pathological results of combined biopsy as the gold standard, we compared the diagnostic efficacy of TBx only, SBx only, and TBx+6-core SBx for PCa/csPCa. The patients were grouped according to mpMRI T-stage (cT2, cT3, cT4) and the detection rates of different biopsy schemes for PCa/csPCa were compared using Cochran's Q and McNemar tests. Results: Among 585 patients with a PI-RADS score of 5, 560 (95.7%) were positive and 25(4.3%) were negative via TBx+SBx. After stratified according to mpMRI T-stage, 233 patients (39.8%) were found in cT2 stage, 214 patients (36.6%) in cT3 stage, and 138 patients (23.6%) in cT4 stage. There was no statistically significant difference in the detection rate of PCa/csPCa between TBx+6-core SBx and TBx+SBx (all P>0.999). Also, there was no statistically significant difference in the detection rate of PCa/csPCa between TBx and TBx+SBx in the cT2, cT3, and cT4 subgroups (PCa: P=0.203, P=0.250, P>0.999; csPCa: P=0.700, P=0.250, P>0.999). The missed diagnosis rate of SBx for PCa and csPCa was 2.1% (12/560) and 1.8% (10/549), and that of TBx for PCa and csPCa was 1.8% (10/560) and 1.4% (8/549), respectively. However, the detection rate of TBx+6-core SBx for PCa and csPCa was 100%. Compared with TBx+SBx, TBx and TBx+6-core SBx had a fewer number of cores and a higher detection rate per core (P < 0.001). Conclusion: For patients with a PI-RADS score of 5, TBx and TBx+6-core SBx showed the same PCa/csPCa detection rates and a high detection rates per core as that of TBx+SBx, which can be considered as an optimal scheme for prostate biopsy.

Key words: Prostatic neoplasms, Biopsy, Magnetic resonance imaging, Prostate imaging reporting and data system

CLC Number: 

  • R737.25

Table 1

mpMRI acquisition parameters"

mpMRI protocol TR/TE FOV Matrix Slice thickness/Gap Flip angle
T2WI 3 200 ms/85 ms 240 mm×240 mm 320×256 4 mm/0 mm 90°
DWI 3 000 ms/60 ms 240 mm×240 mm 96×96 4 mm/0 mm 90°
DCE 5.0 ms/1.7 ms 240 mm×192 mm 192×128 3 mm/0 mm 15°

Figure 1

Several prostate biopsy sampling schemes SBx, systematic biopsy; TBx, targeted biopsy."

Table 2

Clinical characteristics of PI-RADS 5 patients"

Items Total (n=585) cT2 (n=233) cT3 (n=214) cT4 (n=138) P
Age/years 70 (64, 76) 69 (64, 75) 71 (65, 77) 70 (65, 76) 0.068
tPSA/(ng/mL) 25.4 (13.0, 73.6) 15.8 (10.3, 25.0) 35.5 (15.4, 80.5) 88.8 (31.7, 199.5) ＜0.001
PV/mL 49 (36, 70) 41 (30, 55) 47 (36, 65) 70 (55, 95) ＜0.001
PSAD/(ng/mL2) 0.57 (0.30, 1.30) 0.39 (0.23, 0.65) 0.74 (0.36, 1.52) 1.20 (0.46, 3.16) ＜0.001
Dmax/cm 2.6 (1.9, 3.6) 2.0 (1.6, 2.4) 2.8 (2.0, 3.5) 4.0 (3.0, 4.9) ＜0.001
Zone ＜0.001
  PZ only 161 (27.5) 78 (33.5) 71 (33.2) 12 (8.7)
  TZ only 75 (12.8) 65 (27.9) 6 (2.8) 4 (2.9)
  PZ+TZ 349 (59.7) 90 (38.6) 137 (64.0) 122 (88.4)
PCa 560 (95.7) 217 (93.1) 207 (96.7) 136 (98.6) 0.003
csPCa 549 (93.8) 208 (89.3) 206 (96.3) 135 (97.8) 0.001

Figure 2

Detection of PCa using several prostate biopsy sampling schemes TBx, targeted biopsy; SBx, systematic biopsy; nPCa, non-prostate can-cer; csPCa, clinically significant prostate cancer; cisPCa, clinically insignificant prostate cancer."

Table 3

Number of cores using different prostate biopsy sampling schemes"

Items TBx SBx TBx+SBx TBx+6-core SBx P
Number of biopsy cores, median (Q1, Q3) 2 (2, 2) 10 (8, 12) 12(10, 14) 8(8, 8) ＜0.001
Number of positive cores, median (Q1, Q3) 2 (2, 2) 5 (3, 6) 8(6, 8) 6(4, 7) ＜0.001
Detection rate per core 89.7% 56.9% 63.4% 87.1% ＜0.001

Table 4

Diagnostic efficacy of PCa and csPCa using several prostate biopsy sampling schemes for cT2-cT4 patients"

Items SEN/% ACC/% NPV/% AUC (95%CI) P value Kappa
cT2 (n=233)
  PCa (n=217)
     TBx 97.2 97.4 72.7 0.986 (0.973-1.000) 0.203 0.828
     SBx 95.4 95.7 61.5 0.977 (0.959-0.995) 0.002 0.740
     TBx+6-core SBx 100.0 100.0 100.0 1.000 (1.000-1.000) ＞0.999 1.000
  csPCa (n=208)
     TBx 98.1 98.3 86.2 0.990 (0.979-1.000) 0.700 0.916
     SBx 95.7 96.1 73.5 0.978 (0.961-0.995) 0.004 0.826
     TBx+6-core SBx 100.0 100.0 100.0 1.000 (1.000-1.000) ＞0.999 1.000
cT3 (n=214)
  PCa (n=207)
     TBx 98.6 98.6 70.0 0.993 (0.983-1.000) 0.250 0.816
     SBx 99.5 99.5 87.5 0.998 (0.992-1.000) ＞0.999 0.931
     TBx+6-core SBx 100.0 100.0 100.0 1.000 (1.000-1.000) ＞0.999 1.000
  csPCa (n=206)
     TBx 98.5 99.5 99.2 0.993 (0.983-1.000) 0.250 0.835
     SBx 99.5 99.8 99.7 0.998 (0.992-1.000) ＞0.999 0.939
     TBx+6-core SBx 100.0 100.0 100.0 1.000 (1.000-1.000) ＞0.999 1.000
cT4 (n=138)
  PCa (n=136)
     TBx 99.3 99.3 66.7 0.996 (0.987-1.000) ＞0.999 0.796
     SBx 99.3 99.3 66.7 0.996 (0.987-1.000) ＞0.999 0.796
     TBx+6-core SBx 100.0 100.0 100.0 1.000 (1.000-1.000) ＞0.999 1.000
  csPCa (n=135)
     TBx 99.3 99.3 75.0 0.996 (0.987-1.000) ＞0.999 0.854
     SBx 100.0 100.0 100.0 1.000 (1.000-1.000) ＞0.999 1.000
     TBx+6-core SBx 100.0 100.0 100.0 1.000 (1.000-1.000) ＞0.999 1.000
1 Culp MB , Soerjomataram I , Efstathiou JA , et al. Recent global patterns in prostate cancer incidence and mortality rates[J]. Eur Urol, 2020, 77 (1): 38- 52.
doi: 10.1016/j.eururo.2019.08.005
2 Shen WW , Cui LG , Ran WQ , et al. Targeted biopsy with reduced number of cores: Optimal sampling scheme in patients undergoing magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy[J]. Ultrasound Med Biol, 2020, 46 (5): 1197- 1207.
doi: 10.1016/j.ultrasmedbio.2020.01.017
3 Raman AG , Sarma KV , Raman SS , et al. Optimizing spatial biopsy sampling for the detection of prostate cancer[J]. J Urol, 2021, 206 (3): 595- 603.
doi: 10.1097/JU.0000000000001832
4 Barkovich EJ , Shankar PR , Westphalen AC . A systematic review of the existing prostate imaging reporting and data system version 2 (PI-RADS v2) literature and subset meta-analysis of PI-RADSv2 categories stratified by Gleason scores[J]. AJR Am J Roentge-nol, 2019, 212 (4): 847- 854.
doi: 10.2214/AJR.18.20571
5 Stabile A , Giganti F , Kasivisvanathan V , et al. Factors influencing variability in the performance of multiparametric magnetic resonance imaging in detecting clinically significant prostate can-cer: A systematic literature review[J]. Eur Urol Oncol, 2020, 3 (2): 145- 167.
doi: 10.1016/j.euo.2020.02.005
6 Hansen NL , Barrett T , Lloyd T , et al. Optimising the number of cores for magnetic resonance imaging-guided targeted and systema-tic transperineal prostate biopsy[J]. BJU Int, 2020, 125 (2): 260- 269.
doi: 10.1111/bju.14865
7 涂祥, 熊性宇, 张驰宸, 等. 6针系统穿刺联合3针磁共振引导靶向穿刺对前列腺癌的检出效果[J]. 中华泌尿外科杂志, 2022, 43 (12): 914- 919.
8 Aminsharifi A , Gupta RT , Tsivian E , et al. Reduced core targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging-transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies: An alternative template for prostate fusion biopsy[J]. Eur J Radiol, 2019, 110, 7- 13.
doi: 10.1016/j.ejrad.2018.11.006
9 Teraoka S , Honda M , Shimizu R , et al. Optimal number of systematic biopsy cores used in magnetic resonance imaging/transrectal ultrasound fusion targeted prostate biopsy[J]. Yonago Acta Med, 2021, 64 (3): 260- 268.
doi: 10.33160/yam.2021.08.004
10 Sigle A , Suarez-Ibarrola R , Benndorf M , et al. Individualized decision making in transperineal prostate biopsy: Should all men undergo an additional systematic biopsy?[J]. Cancers (Basel), 2022, 14 (21): 5230.
doi: 10.3390/cancers14215230
[1] Chang-wei YUAN,De-run LI,Zhi-hua LI,Yi LIU,Gang-zhi SHAN,Xue-song LI,Li-qun ZHOU. Application of dynamic contrast enhanced status in multiparametric magnetic resonance imaging for prostatic cancer with PI-RADS 4 lesion [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 838-842.
[2] Qiang FU,Guan-ying GAO,Yan XU,Zhuo-hua LIN,You-jing SUN,Li-gang CUI. Comparative study of ultrasound and magnetic resonance imaging in the diagnosis of asymptomatic anterosuperior acetabular labrum tears [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 665-669.
[3] Ying LIU,Ran HUO,Hui-min XU,Zheng WANG,Tao WANG,Hui-shu YUAN. Correlations between plaque characteristics and cerebral blood flow in patients with moderate to severe carotid stenosis using magnetic resonance vessel wall imaging [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 646-651.
[4] Yan XIONG,Xin LI,Li LIANG,Dong LI,Li-min YAN,Xue-ying LI,Ji-ting DI,Ting LI. Evaluation of accuracy of pathological diagnosis based on thyroid core needle biopsy [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 234-242.
[5] Dan-feng ZHENG,Jun-yu LI,Jia-xi LI,Ying-shuang ZHANG,Yan-feng ZHONG,Miao YU. Pathologic features of paraspinal muscle biopsies in patients with adolescent idiopathic scoliosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 283-291.
[6] Shan YE,Ping-ping JIN,Nan ZHANG,Hai-bo WU,Lin SHI,Qiang ZHAO,Kun YANG,Hui-shu YUAN,Dong-sheng FAN. Cortical thickness and cognitive impairment in patients with amyotrophic lateral sclerosis [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1158-1162.
[7] Ying CAI,Qiao-qin WAN,Xian-jie CAI,Ya-juan GAO,Hong-bin HAN. Epidural photobiomodulation accelerates the drainage of brain interstitial fluid and its mechanism [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 1000-1005.
[8] WANG Shu-lei,GAO Yang-xu,ZHANG Hong-wu,YANG Hai-bo,LI Hui,LI Yu,SHEN Li-xue,YAO Hong-xin. Clinical analysis of 30 cases of basal ganglia germinoma in children [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 222-226.
[9] ZHANG Fan,CHEN Qu,HAO Yi-chang,YAN Ye,LIU Cheng,HUANG Yi,MA Lu-lin. Relationship between recovery of urinary continence after laparoscopic radical prostatectomy and preoperative/postoperative membranous urethral length [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 299-303.
[10] Yi-fan WU,Xiao-yuan ZHANG,Shuang REN,Ying-xiang YU,Cui-qing CHANG. Measurement and evaluation of the quadriceps muscle mass in young men based on magnetic resonance imaging [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 843-849.
[11] ZHOU Guang-ping,ZHOU Qian-yun,ZHU Ji-hong. A case report of TAFRO syndrome [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 814-817.
[12] ZHANG Lei,LI Guo-liang,DANG Zong-hui, ,A yong,WU Ling-jie,LIU Li-jun. Analysis of bleeding risk in percutaneous renal biopsy in Tibet [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 298-301.
[13] WANG Ying-chun,HUANG Yong-hui,CHANG Hong,YAO Wei,YAN Xiu-e,LI Ke,ZHANG Yao-peng,ZHENG Wei. Characteristics of benign and malignant lesions of ampullary polyps and the accuracy of forceps biopsy [J]. Journal of Peking University (Health Sciences), 2021, 53(1): 204-209.
[14] Hui SHENG,Lei LIANG,Tong-liang ZHOU,Yan-xing JIA,Tong WANG,Lan YUAN,Hong-bin HAN. Improved synthesis process of optical-magnetic bimodal probe of Gd-[4,7-Bis-carboxymethyl-10-(2-fluoresceinthioureaethyl)-1,4,7,10-tetraaza-cyclododec-1-yl]-acetic acid complexes [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 959-963.
[15] Yi-chang HAO,Ye YAN,Fan ZHANG,Min QIU,Lang ZHOU,Ke LIU,Jian LU,Chun-lei XIAO,Yi HUANG,Cheng LIU,Lu-lin MA. Surgical strategy selection and experience summary of prostate cancer with positive single needle biopsy [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 625-631.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd